Back
2019
Deal

Oculis in-licenses novel phase II-stage Anti-TNF alpha antibody fragment

Oculis SA, a clinical-stage biopharmaceutical company developing next-generation topical ophthalmic treatments in Lausanne, has entered into an agreement to in license a novel topical anti-TNF alpha antibody from Novartis. The compound, named LME 636 which will be renamed OCS-02, is based on a proprietary single-chain antibody fragment technology specifically designed for topical delivery.

The VISCHER-team advising Oculis is led by Christian Wyss (Partner) with Vincent Reardon (Senior Associate) and Vera Keller (all Corporate) and Adrian Briner (Associate) Tax.

Blogs and special topics

Our specialists blog and websites on selected topics will keep you informed of the latest developments and discussions.

Learn more …

News Alerts

Here you will find the frequent news alerts in the fields tax, litigation and arbitration, public sector and regulatory, corporate and commercial law and intellectual property law.

Learn more

Subscribe to news alert

Contact

VISCHER AG, Zürich
Schützengasse 1, Postfach, 8021 Zürich
Phone +41 58 211 34 00

VISCHER AG, Basel
Aeschenvorstadt 4, Postfach, 4010 Basel
Phone +41 58 211 33 00

Map and Directions